[go: up one dir, main page]

AR021370A1 - Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides - Google Patents

Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides

Info

Publication number
AR021370A1
AR021370A1 ARP990105953A ARP990105953A AR021370A1 AR 021370 A1 AR021370 A1 AR 021370A1 AR P990105953 A ARP990105953 A AR P990105953A AR P990105953 A ARP990105953 A AR P990105953A AR 021370 A1 AR021370 A1 AR 021370A1
Authority
AR
Argentina
Prior art keywords
injectable pharmaceutical
pharmaceutical compositions
compositions containing
stabilized injectable
neoplasic
Prior art date
Application number
ARP990105953A
Other languages
English (en)
Original Assignee
Mylan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Pharmaceuticals Inc filed Critical Mylan Pharmaceuticals Inc
Publication of AR021370A1 publication Critical patent/AR021370A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica inyectable para administracion en humanos que comprende una solucion de: (a) un compuesto anti-neoplásico, (b) un agentesolubilizante/dispersante, y (c) una cantidad de antioxidante suficiente para estabilizar elcompuest o anti-neoplásico.
ARP990105953A 1998-12-02 1999-11-23 Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides AR021370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/203,350 US6071952A (en) 1998-12-02 1998-12-02 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents

Publications (1)

Publication Number Publication Date
AR021370A1 true AR021370A1 (es) 2002-07-17

Family

ID=22753614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105953A AR021370A1 (es) 1998-12-02 1999-11-23 Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides

Country Status (8)

Country Link
US (2) US6071952A (es)
EP (1) EP1135120A2 (es)
JP (1) JP2003526612A (es)
CN (1) CN1329488A (es)
AR (1) AR021370A1 (es)
AU (1) AU771577B2 (es)
NZ (1) NZ512686A (es)
WO (1) WO2000032186A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642285B1 (en) * 1999-02-02 2003-11-04 Robert Mathys Stiftung Implant comprising calcium cement and hydrophobic liquid
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CN101574318B (zh) * 2009-05-31 2011-06-15 海口市制药厂有限公司 一种紫杉醇注射液的制备方法
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
JP6124633B2 (ja) * 2013-03-18 2017-05-10 ダイト株式会社 安定なドセタキセル注射剤
DE112014005175T5 (de) 2013-11-13 2016-07-21 Euro-Celtique S.A. Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623095B2 (ja) * 1983-03-03 1994-03-30 森下ルセル株式会社 制癌剤を含有するエマルジヨン製剤
FI883337L (fi) * 1987-07-16 1989-01-17 Bristol Myers Co Icke-vattenloesningar av doxorubicinhydroklorin.
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
RU2077885C1 (ru) * 1992-06-25 1997-04-27 Московский научно-исследовательский онкологический институт им.П.А.Герцена Противоопухолевое средство для местного лечения злокачественных опухолей
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
ATE314845T1 (de) * 1993-07-29 2006-02-15 Us Health Verwendung von paclitaxel und seinen derivaten zur herstellung eines medikaments für die behandlung von restenose
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU6787398A (en) * 1997-03-27 2000-01-05 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of aids-associated kaposi's sarcoma
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions

Also Published As

Publication number Publication date
US6153644A (en) 2000-11-28
AU771577B2 (en) 2004-03-25
JP2003526612A (ja) 2003-09-09
EP1135120A2 (en) 2001-09-26
US6071952A (en) 2000-06-06
CN1329488A (zh) 2002-01-02
AU2033300A (en) 2000-06-19
NZ512686A (en) 2005-05-27
WO2000032186A3 (en) 2000-11-16
WO2000032186A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
AR002007A1 (es) UNA COMPOSICION TERAPEUTICA DE APLICACION TOPICA QUE CONTIENE UN ANTAGONISTA DE SUSTANCIA P Y UTILIZACION DE DICHO ANTAGONISTA PARA LAPREPARACIóN DE DICHA COMPOSICION PARA DISMINUIR Y/O ELIMINAR UN EFECTO SECUNDARIO IRRITANTE DE UN PRODUCTO CONTENIDO EN LA MISMA.
BR9810495A (pt) Composição farmacêutica
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR0107869A (pt) Composições farmacêuticas eletrogiradas
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
PT1073467E (pt) Formulacoes de co-solvente que compreendem um composo de vitamina d.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
DE60318447D1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR046853A1 (es) Mezclas insecticidas que contienen triflumuron con actividad sinergica
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.

Legal Events

Date Code Title Description
FC Refusal